Prosecution Insights
Last updated: October 01, 2026
Application No. 18/874,772

WATER-IN-OIL EMULSIFIED SOLID COSMETIC

Non-Final OA §103
Filed
Dec 13, 2024
Priority
Jul 14, 2022 — JP 2022-113474 +1 more
Examiner
PALLAY, MICHAEL B
Art Unit
Tech Center
Assignee
SHISEIDO Company, Ltd.
OA Round
1 (Non-Final)
56%
Grant Probability
Moderate
1-2
OA Rounds
1y 4m
Est. Remaining
90%
With Interview

Examiner Intelligence

Grants 56% of resolved cases
56%
Career Allowance Rate
413 granted / 740 resolved
-4.2% vs TC avg
Strong +34% interview lift
Without
With
+34.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
65 currently pending
Career history
783
Total Applications
across all art units

Statute-Specific Performance

§101
2.5%
-37.5% vs TC avg
§103
48.2%
+8.2% vs TC avg
§102
11.7%
-28.3% vs TC avg
§112
24.2%
-15.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 740 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-9 is/are rejected under 35 U.S.C. 103 as being unpatentable over Tajima et al. (US 2017/0056302 A1; published 02 March 2017) in view of Souda et al. (US 2013/0210930 A1; published 15 August 2013). Tajima et al. discloses a water-in-oil emulsion solid cosmetic, comprising: an external oil phase comprising a liquid oil thickened or solidified with (A) wax and (B) disteardimonium hectorite; and an internal water phase comprising (C) an internal phase powder dispersed in an aqueous medium (claim 1) wherein the internal phase powder is a powder that may usually be used in cosmetics (paragraph [0040]) wherein the internal phase powder may be inorganic powder, mica, silica, or talc (paragraph [0041]) wherein the external oil phase may contain an external phase powder (paragraph [0052]) such as including a powder such as in the internal phase powder (paragraph [0053]) which may be an organic pigment (i.e., a color material) (paragraph [0041]) wherein the liquid oil may comprise nonvolatile linear silicone oil (paragraph [0033]) wherein the liquid oil is preferably 20-70% by mass of the solid cosmetic (paragraph [0037]) wherein the oil component may comprise semisolid oils (paragraph [0056]) wherein the wax may be lanolin (i.e., a semisolid oil) (paragraph [0025]) wherein wax may be 0.1-30% by mass of the solid cosmetic (paragraph [0027]) wherein the solid cosmetic may contain 2% by mass PEG-10 dimethicone (i.e., film-forming agent) (Formulation Examples 1, 2; paragraphs [0092], [0098]) wherein the solid cosmetic is suitable for being provided as a makeup cosmetic (paragraph [0067]). Although Tajima et al. does not disclose a specific formulation including all constituents as discussed above, it would have been prima facie obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to follow the suggestions of Tajima et al. as discussed above and to make the solid cosmetic of Tajima et al. as discussed above with all the constituents as discussed above, with a reasonable expectation of success. Regarding the recitation of 15 mass% or more of residual oil in claim 6, the disclosures of Tajima et al. of liquid oil comprising nonvolatile linear silicone oil wherein the liquid oil is 20-70% by mass of the solid cosmetic as discussed above, results in 20-70% by mass nonvolatile (i.e., residual) linear silicone oil in the solid cosmetic of Tajima et al. Regarding the recitation of 15 mass% or less of semisolid oil in claim 7, the disclosures of Tajima et al. of the oil component comprising semisolid oil and of wax being lanolin (i.e., a semisolid oil) and wax being 0.1-30% by mass of the solid cosmetic, results in 0.1-30% by mass lanolin (i.e., a semisolid oil) in the solid cosmetic of Tajima et al., which overlaps the claimed range of 15 mass% or less, and a prima facie case of obviousness exists where prior art and claimed ranges overlap per MPEP 2144.05(I). Tajima et al. does not disclose that the internal phase powder has an average primary particle size of 1.0 µm or more as claimed. Souda et al. discloses cosmetic emulsions (title) such as water-in-oil emulsions (paragraph [0148]) which can be in the form of makeup product such as lipstick (paragraph [0264]) wherein average primary particle size of powders therein is preferably 1 nm to 100 µm (paragraph [0108]). It would have been prima facie obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to combine the teachings of Tajima et al. and Souda et al. by using powder having average primary particle size of 1 nm to 100 µm as suggested by Souda et al. as the powder in the solid cosmetic of Tajima et al. as discussed above, with a reasonable expectation of success. A person of ordinary skill in the art before the effective filing date of the claimed invention would have been motivated to do so to use powder that has particle size known to be suitable for use in cosmetic water-in-oil emulsions as suggested by Souda et al., given that the selection of a known material based on its suitability for its intended use supports a prima facie obviousness determination per MPEP 2144.07. Such range of 1 nm to 100 µm overlaps the claimed range of 1.0 µm or more, and a prima facie case of obviousness exists where prior art and claimed ranges overlap per MPEP 2144.05(I). Regarding claim 9, it would have been prima facie obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to further combine the teachings of Tajima et al. and Souda et al. by making the water-in-oil solid cosmetic of Tajima et al. in view of Souda et al. as discussed above in the form of a lipstick as in Souda et al. A person of ordinary skill in the art before the effective filing date of the claimed invention would have been motivated to do so to formulate the water-in-oil solid cosmetic in a known makeup form such as a lipstick as suggested by Souda et al., given that Tajima et al. suggests formulation as a makeup, and given that the selection of a known material based on its suitability for its intended use supports a prima facie obviousness determination per MPEP 2144.07. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICHAEL B. PALLAY whose telephone number is (571)270-3473. The examiner can normally be reached Monday through Friday from 8:30 AM to 5:00 PM Eastern Time. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sue Liu can be reached at (571)272-5539. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MICHAEL B. PALLAY/Primary Examiner, Art Unit 1617
Read full office action

Prosecution Timeline

Dec 13, 2024
Application Filed
Aug 25, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12746351
HIGH BARRIER POWDER CAPSULE
4y 1m to grant Granted Sep 29, 2026
Patent 12740560
METHODS OF CONTROLLING OR PREVENTING INFESTATION OF BANANA PLANTS BY PHYTOPATHOGENIC MICROORGANISMS OF THE GENUS PSEUDOCERCOSPORA
4y 5m to grant Granted Sep 22, 2026
Patent 12734183
PHARMACEUTICAL COMPOSITIONS FOR RELIEF OF COVID-19 SYMPTOMS AND METHODS OF PRODUCING AND USING THEM
3y 10m to grant Granted Sep 15, 2026
Patent 12691078
STABLE COMPOSITIONS OF FUNCTIONAL INGREDIENTS AND METHODS OF MAKING THE SAME
3y 10m to grant Granted Jul 28, 2026
Patent 12690592
SYSTEMS AND METHODS FOR USE OF CHLORINE DIOXIDE IN CULTIVATION AND POST-HARVEST APPLICATIONS
3y 0m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
56%
Grant Probability
90%
With Interview (+34.0%)
3y 2m (~1y 4m remaining)
Median Time to Grant
Low
PTA Risk
Based on 740 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month